Myrelez (Lanreotide Acetate)

Lanreotide acetate mimics natural somatostatin and binds to somatostatin receptors, mainly sst2 and sst5, on pituitary and neuroendocrine cells. This binding inhibits adenylate cyclase, decreasing cyclic AMP and suppressing the release of growth hormone, insulin, glucagon, and other peptide hormones involved in disease activity.

The dosage of Myreotide is individualized by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. Dosing regimens typically involve subcutaneous injections administered at regular intervals, often monthly, but the exact schedule and amount are determined by the treating physician.

Safety of Myrelez during pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women of child‑bearing potential should be advised of the unknown risks and use effective contraception.

To order Myrelez, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and assist with import documentation.

The primary alternative to Myrelez is octreotide, another somatostatin analogue. Both agents suppress hormone secretion, but lanreotide has a longer dosing interval (often monthly) compared with octreotide’s more frequent dosing. Clinical efficacy is comparable, while individual tolerability and injection‑site reactions may differ, influencing physician and patient preference.

Myrelez should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at controlled room temperature is unavoidable, limit exposure to no more than 24 hours and return to refrigeration promptly.

Myrelez is administered by subcutaneous injection, usually into the abdomen, thigh or upper arm. The injection is performed by a healthcare professional or a trained patient following aseptic technique. The recommended injection volume and site rotation are outlined in the prescribing information to minimize local reactions.

Serious adverse events include gallstone formation or biliary colic, acute pancreatitis, severe hyperglycemia, and hypersensitivity reactions such as anaphylaxis. Patients should be monitored for abdominal pain, jaundice, sudden changes in blood glucose, or signs of allergic reaction, and seek immediate medical attention if these occur.

Myrelez is contraindicated in individuals with known hypersensitivity to lanreotide acetate or any of the excipients in the formulation. Caution is advised for patients with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease. Pregnant or breastfeeding women should only use it when the potential benefit justifies the potential risk.